246 related articles for article (PubMed ID: 24336963)
21. Discovery of
Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
[TBL] [Abstract][Full Text] [Related]
22. Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis.
Nakao KT; Usui T; Ikeda M; Mori Y; Yamamoto T; Kawashima ST; Nanba K; Yuno A; Tamanaha T; Tagami T; Naruse M; Asato R; Shimatsu A
Head Neck; 2013 Dec; 35(12):E363-8. PubMed ID: 23468374
[TBL] [Abstract][Full Text] [Related]
23. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2013 Oct; 23(20):5721-6. PubMed ID: 23993776
[TBL] [Abstract][Full Text] [Related]
24. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance profiles of mutations in the RET kinase domain.
Liu X; Shen T; Mooers BHM; Hilberg F; Wu J
Br J Pharmacol; 2018 Sep; 175(17):3504-3515. PubMed ID: 29908090
[TBL] [Abstract][Full Text] [Related]
26. Disease-causing mutation in extracellular and intracellular domain of FGFR1 protein: computational approach.
Rajith B; George Priya Doss C
Appl Biochem Biotechnol; 2013 Mar; 169(5):1659-71. PubMed ID: 23329143
[TBL] [Abstract][Full Text] [Related]
27. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
28. In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.
Tanneeru K; Balla AR; Guruprasad L
J Biomol Struct Dyn; 2015; 33(8):1710-9. PubMed ID: 25245460
[TBL] [Abstract][Full Text] [Related]
29. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
[TBL] [Abstract][Full Text] [Related]
30. Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E; Oktay L; Tunc H; Durdagi S
ChemMedChem; 2024 Jun; 19(12):e202300644. PubMed ID: 38523069
[TBL] [Abstract][Full Text] [Related]
31. Construction and validation of a RET TK catalytic domain by homology modeling.
Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
[TBL] [Abstract][Full Text] [Related]
32. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
33. Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants.
Toenjes ST; Garcia V; Maddox SM; Dawson GA; Ortiz MA; Piedrafita FJ; Gustafson JL
ACS Chem Biol; 2019 Sep; 14(9):1930-1939. PubMed ID: 31424197
[TBL] [Abstract][Full Text] [Related]
34. Mammal-restricted elements predispose human RET to folding impairment by HSCR mutations.
Kjaer S; Hanrahan S; Totty N; McDonald NQ
Nat Struct Mol Biol; 2010 Jun; 17(6):726-31. PubMed ID: 20473317
[TBL] [Abstract][Full Text] [Related]
35. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
[TBL] [Abstract][Full Text] [Related]
37. Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.
Shehata MA; Contreras J; Martín-Hurtado A; Froux A; Mohamed HT; El-Sherif AA; Plaza-Menacho I
J Adv Res; 2023 Mar; 45():87-100. PubMed ID: 35595215
[TBL] [Abstract][Full Text] [Related]
38. Structure and chemical inhibition of the RET tyrosine kinase domain.
Knowles PP; Murray-Rust J; Kjaer S; Scott RP; Hanrahan S; Santoro M; Ibáñez CF; McDonald NQ
J Biol Chem; 2006 Nov; 281(44):33577-87. PubMed ID: 16928683
[TBL] [Abstract][Full Text] [Related]
39. Blocking the interaction between HIV-1 integrase and human LEDGF/p75: mutational studies, virtual screening and molecular dynamics simulations.
Reddy KK; Singh P; Singh SK
Mol Biosyst; 2014 Mar; 10(3):526-36. PubMed ID: 24389668
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.
Han M; Li S; Ai J; Sheng R; Hu Y; Hu Y; Geng M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5679-5684. PubMed ID: 27815117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
